The federal Food and DrugAdministration said it approved for U.S. marketing a drug thatreduces bleeding in hemophiliacs requiring dental work.    The FDA said the drug, tranemaxic acid, would lessen and insome cases eliminate altogether the need for blood transfusionsin hemophiliacs who must have teeth extracted.    The drug will be made by Kabivitrum of Stockholm, Swedenand distributed here under the trade name Cyklokapron byKabivitrum Inc of Alameda, Calif.    Hemophilia is a hereditary diseease whose victims lack theparticular proteins that promote blood clotting. Reuter&#3;